Cargando...
Belimumab for systemic lupus erythematosus
BACKGROUND: Belimumab, the first biologic approved for the treatment of systemic lupus erythematosus (SLE), has been shown to reduce autoantibody levels in people with SLE and help control disease activity. OBJECTIVES: To assess the benefits and harms of belimumab (alone or in combination) in system...
Guardado en:
| Publicado en: | Cochrane Database Syst Rev |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
John Wiley & Sons, Ltd
2021
|
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8095005/ https://ncbi.nlm.nih.gov/pubmed/33631841 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010668.pub2 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|